Неспецифическая профилактика острых респираторных вирусных инфекций: подводные камни и новые факты

1. Острые инфекции дыхательных путей у детей. Диагностика, лечение, профилактика: клиническое руководство. Под ред. Н.А. Геппе. М.: МедКом-Про, 2018 [Acute respiratory tract infections in children. Diagnostics, treatment, prevention: clinical guidelines. NA Geppe (Ed.). Moscow: MedKom-Pro, 2018 (in Russian)].
2. Викулов Г.Х. Новые и возвращающиеся респираторные вирусные инфекции: алгоритмы диагностики и терапии. РМЖ. Медицинское обозрение. 2018; 2 (8–1): 5–11 ­[Vikulov GKh. Novye i vozvrashchaiushchiesia respiratornye virusnye infektsii: algoritmy diagnostiki i terapii. RMZh. Meditsinskoe obozrenie. 2018; 2 (8–1): 5–11 (in Russian)].
3. Гаращенко Т.И., Гаращенко М.В., Мезенцева М.В. Клинико-иммунологическое обоснование гомеопатических препаратов в профилактике и лечении гриппа и ОРВИ. Рус. мед. журн. 2005; 13 (21): 1432–7 [Garashchenko TI, Garashchenko MV, Mezentseva MV. Kliniko-immunologicheskoye obosnovaniye gomeopaticheskikh preparatov v profilaktike i lechenii grippa i ORVI. Rus. med. zhurn. 2005; 13 (21): 1432–7 (in Russian)].
4. Гаращенко М.В., Ильенко Л.И., Гаращенко Т.И., Мезенценва М.В. Клинико-иммунологическое обоснование применения Афлубина в профилактике и лечении вирусных заболеваний респираторного тракта у детей. Детские инфекции. 2005; 3: 49–3 [Garashchenko MV, Il'yenko LI, Garashchenko TI, Mezentsenva MV. Kliniko-immunologicheskoye obosnovaniye primeneniya Aflubina v profilaktike i lechenii virusnykh zabolevaniy respiratornogo trakta u detey. Detskiye infektsii. 2005; 3: 49–3 (in Russian)].
5. Ильенко Л.И., Гуреев А.Н., Гайнова Л.В., Богданова С.В. Оценка клинической эффективности комплексных гомеопатических препаратов с позиции доказательной медицины. В кн.: Гомеопатический ежегодник – 2019. Сборник материалов XXIX Научно-практической конференции. 2019; с. 138–42 [Ilyenko LI, Gureev AN, Gainova LV, Bogdanova SV. Evaluation of the clinical efficacy of complex homeopathic medicines from the standpoint of evidence-based medicine. In: Homeopathic Yearbook – 2019. Collection of materials of the XXIX Scientific and Practical Conference. 2019; p. 138–42 (in Russian)].
6. ПРИМА: педиатрические рекомендации по иммуномодулирующим препаратам в амбулаторной практике (консенсус). 2-е изд., перераб. и доп. М.: РГ-Пресс, 2017 [PRIMA: Pediatric recommendations for immunomodulatory drugs in outpatient practice (consensus). 2nd ed., rev. and add. Moscow: RG-Press, 2017 (in Russian)].
7. Ильенко Л.И., Гаращенко Т.И., Холодова И.Н., и др. Часто болеющий ребенок. Клинико-экспериментальное и экономическое обоснование новых технологий профилактических и восстановительных мероприятий в амбулаторно-поликлинических условиях. М., 2008 [Ilienko LI, Garashchenko TI, Kholodova IN, et al. A frequently ill child. Clinical and experimental and economic substantiation of new technologies for preventive and restorative measures in outpatient settings. Moscow, 2008 (in Russian)].
8. Ершов Ф.И. Рациональная фармакотерапия гриппа и ОРВИ. Фармацевтический вестник. 2003; 33: 39–43 [Ershov FI. Ratsional'naia farmakoterapiia grippa i ORVI. Farmatsevticheskii vestnik. 2003; 33: 39–43 (in Russian)].
9. Еропкин М.Ю., Гудкова Т.М., Даниленко Д.М., и др. Пандемический грипп 2009 г. в России. РМЖ. 2010; 18 (7): 410–5 [Eropkin MIu, Gudkova TM, Danilenko DM, et al. Pandemicheskii gripp 2009 g. v Rossii. RMZh. 2010; 18 (7): 410–5 (in Russian)].
10. Селькова Е.П., Семененко Т.А., Ленева И.А., Бурцева М.И. Гомеопатический препарат Оциллококцинум в лечении и профилактике гриппа и ОРВИ. Трудный пациент. 2006; 11 [Sel'kova EP, Semenenko TA, Leneva IA, Burtseva MI. Gomeopaticheskii preparat Otsillokoktsinum v lechenii i profilaktike grippa i ORVI. Trudnyi patsient. 2006; 11 (in Russian)].
11. Романцов М.Г., Мельникова И.Ю., Смагина А.Н., и др. Эффективность циклоферона и оценка его безопасности при респираторных вирусных инфекциях у детей. Фундаментальные исследования. 2012; 2: 208–14 [Romantsov MG, Mel'nikova IIu, Smagina AN, et al. Effektivnost' tsikloferona i otsenka ego bezopasnosti pri respiratornykh virusnykh infektsiiakh u detei. Fundamental'nye issledovaniia. 2012; 2: 208–14 (in Russian)].
12. Рациональная фармакотерапия часто болеющих детей. Пособие для врачей-педиатров, семейных врачей, студентов медицинских вузов. Под. ред. М.Г. Романцова. СПб., 2006 [Rational pharmacotherapy of frequently ill children. A guide for pediatricians, family doctors, medical students. MG Romantsov (Ed.). Saint Petersburg, 2006 (in Russian)].
13. Фарбер И.М., Геппе Н.А., Рейхарт Д.В., и др. Терапия гриппа и прочих ОРВИ у детей младшего и среднего школьного возраста: влияние препарата ИнгавиринR на интоксикационный, лихорадочный и катаральный синдромы. Рос. вестн. перинатологии и педиатрии. 2016; 61 (2): 115–20 [Farber IM, Geppe NA, Reikhart DV, et al. Terapiia grippa i prochikh ORVI u detei mladshego i srednego shkol'nogo vozrasta: vliianie preparata IngavirinR na intoksikatsionnyi, likhoradochnyi i kataral'nyi sindromy. Ros. vestn. perinatologii i pediatrii. 2016; 61 (2): 115–20 (in Russian)].
14. Ершов Ф.И. Антивирусные препараты: справочник. 2-е изд. М.: ГЭОТАР-Медиа, 2006 [Ershov FI. Antiviral drugs: a reference book. 2nd ed. Moscow: GEOTAR-Media, 2006 (in Russian)].
15. Максакова В.Л., Васильева И.А., Ерофеева М.К. Применение препарата Кагоцел для лечения и профилактики гриппа и других острых респираторных вирусных инфекций. Медлайн-экспресс. 2009; 1: 42–5 [Maksakova VL, Vasil'eva IA, Erofeeva MK. Primenenie preparata Kagotsel dlia lecheniia i profilaktiki grippa i drugikh ostrykh respiratornykh virusnykh infektsii. Medlain-ekspress. 2009; 1: 42–5 (in Russian)].
16. Сологуб Т.В., Шульдяков А.А., Романцов М.Г., и др. Циклоферон как средство лечения и экстренной профилактики гриппа и ОРВИ (многоцентровое рандомизированное контрольно-сравнительное исследование). Антибиотики и химиотерапия. 2009; 7–8: 30–6 [Sologub TV, Shul'diakov AA, Romantsov MG, et al. Tsikloferon kak sredstvo lecheniia i ekstrennoi profilaktiki grippa i ORVI (mnogotsentrovoe randomizirovannoe kontrol'no-sravnitel'noe issledovanie). Antibiotiki i khimioterapiia. 2009; 7–8: 30–6 (in Russian)].
17. Кареткина Г.Н. Применение индукторов интерферонов для лечения и профилактики гриппа и других острых респираторных вирусных инфекций. Лечащий врач. 2009; 10: 1–5 [Karetkina GN. Primenenie induktorov interferonov dlia lecheniia i profilaktiki grippa i drugikh ostrykh respiratornykh virusnykh infektsii. Lechashchii vrach. 2009; 10: 1–5 (in Russian)].
18. Романцов М.Г., Селькова Е.П., Гаращенко М.В., и др. Повышение естественной резистентности детей с целью профилактики гриппа и ОРВИ (результаты многоцентровых рандомизированных исследований). Антибиотики и химиотерапия. 2009; 9–10: 37–41 [Romantsov MG, Sel'kova EP, Garashchenko MV, et al. Povyshenie estestvennoi rezistentnosti detei s tsel'iu profilaktiki grippa i ORVI (rezul'taty mnogotsentrovykh randomizirovannykh issledovanii). Antibiotiki i khimioterapiia. 2009; 9–10: 37–41 (in Russian)].
19. Новикова И.А. Целесообразность применения препаратов интерферонов для профилактики и лечения ОРВИ. Медицинские новости. 2017; 1: 27–30 [Novikova IA. Tselesoobraznost' primeneniia preparatov interferonov dlia profilaktiki i lecheniia ORVI. Meditsinskie novosti. 2017; 1: 27–30 (in Russian)].
20. Ершов Ф.И., Наровлянский А.Н. Теоретические и прикладные аспекты системы интерферонов: к 60-летию открытия интерферонов. Вопросы вирусологии. 2018; 63 (1): 10–8 [Ershov FI, Narovlianskii AN. Teoreticheskie i prikladnye aspekty sistemy interferonov: k 60-letiiu otkrytiia interferonov. Voprosy virusologii. 2018; 63 (1): 10–8 (in Russian)].
21. Романцов М.Г., Шульдяков A.A., Ершов Ф.И., и др. Индукторы эндогенного интерферона в инфектологии (Научный обзор). Профилактическая медицина. 2013; 1–2: 77–83 [Romantsov MG, Shul'diakov AA, Ershov FI, et al. Induktory endogennogo interferona v infektologii (Nauchnyi obzor). Profilakticheskaia meditsina. 2013; 1–2: 77–83 (in Russian)].
22. Forsbach A, Muller Ch, Montino C, et al. Negative regulation of the type I interferon signaling pathway by synthetic Toll-like receptor 7 ligands. J Interferon Cytokine Res 2012; 6: 254–68.
23. Титов Л.П., Карпов И.А. Противовирусный иммунитет: молекулярно-клеточные механизмы, закономерности развития и иммунопатология. Мед. журн. 2007; 1: 4–14 ­[Titov LP, Karpov IA. Protivovirusnyi immunitet: molekuliarno-kletochnye mekhanizmy, ­zakonomernosti razvitiia i immunopatologiia. Med. zhurn. 2007; 1: 4–14 (in Russian)].
24. Booy S, Hofland L, van Eijck C. Potentials of interferon therapy in the treatment of pancreatic cancer. J Interferon Cytokine Res 2015; 35: 327–39.
25. Тarhini AA, Lee SJ, Li X, et al. E3611-A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-a2b in Advanced Melanoma. Clin Cancer Res 2019; 25 (2): 524–32.
26. Theocharis SE, Margeli AP, Tsokos MG. Alpha 2b-interferon inhibits rat liver regeneration after partial hepatectomy without affecting thymidine kinase activity. J Lab Clin Med 1995; 125 (5): 588–96.
27. Kaneko N, Kudo K, Mabuchi T, et al. Suppression of cell proliferation by interferon-alpha through interleukin-1 production in adult rat dentate gyrus. Neuropsychopharmacology 2006; 31 (12): 2619–26.
28. Yaar M, Karassik RL, Schnipper LE, et al. Effects of alpha and beta interferons on cultured human keratinocytes. J Invest Dermatol 1985; 85 (1): 70–4.
29. Elias JA, Jimenez SA, Freundlich B. Recombinant gamma, alpha, and beta interferon regulation of human lung fibroblast proliferation. Am Rev Respir Dis 1987; 135 (1): 62–5.
30. Vorotelyak EA, Alpeeva EV. Evaluation of the antiproliferative effect of interferon a2b and Oscillococcinum on various human and murine cells cultures. Epub ahead of print.
31. Роговая О.С., Измайлова Л.Ш., Сербина О.О. К вопросу об изучении патогенеза антипролиферативного действия противовирусных препаратов. Инфекционные болезни. 2020; 18 (2): 48–56 [Rogovaia OS, Izmailova LSh, Serbina OO. K voprosu ob izuchenii patogeneza antiproliferativnogo deistviia protivovirusnykh preparatov. Infektsionnye bolezni. 2020; 18 (2): 48–56 (in Russian)].
32. Хабриев Р.У. Руководство по экспериментальному (доклиническому) изучению новых фармакологических веществ. М., 2005 [Khabriev RU. Guidelines for experimental (preclinical) study of new pharmacological substances. Moscow, 2005 (in Russian)].
33. Валиев Т.Т. Клиническое применение интерферонов: современный взгляд на вопросы эффективности и безопасности. Педиатрия. Consilium Medicum. 2020; 3: 95–104 ­[Valiev TT. Interferon clinical use: modern view on efficacy and safety. Literature review. ­Pediatrics. Consilium Medicum. 2020; 3 (in Russian)]. DOI: 10.26442/26586630.2020.3.200286
34. Verma A, Deb DK, Sassano A, et al. Activation of the p38 mitogen-activated protein kinase mediates the suppressive effects of type I interferons and transforming growth factor-b on normal hematopoiesis. J Biol Chem 2002; 277: 7726–35.
35. Orford KW, Scadden DT. Deconstructing stem cell self-renewal: genetic insights into cell-cycle regulation. Nat Rev Genet 2008; 9: 115–28.
36. Baldridge MT, King KY, Goodell MA. Inflammatory signals regulate hematopoietic stem cells. Trends Immunol 2011; 32: 57–65.
37. Selleri C, Sato T, Anderson S, et al. Interferon-gamma and tumor necrosis factoralpha suppress both early and late stages of hematopoiesis and induce programmed cell death. J Cell Physiol 1995; 165: 538–46.
38. Broxmeyer HE, Williams DE, Lu L, et al. The suppressive influences of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: synergism of tumor necrosis factor and interferon-gamma. J Immunol 1986; 136: 4487–95.
39. Hwang JH, Kim SW, Lee HJ, et al. Interferon gamma has dual potential in inhibiting or promoting survival and growth of hematopoietic progenitors: interactions with stromal cell-derived factor 1. Int J Hematol 2006; 84: 143–50.
40. Zeng W, Miyazato A, Chen G, et al. Interferon-gamma-induced gene expression in CD34 cells: identification of pathologic cytokine-specific signature profiles. Blood 2006; 107: 167–75.
41. Baldridge MT, King KY, Boles NC, et al. Quiescent haematopoietic stem cells are activated by IFN-g in response to chronic infection. Nature 2010; 465: 793–7.
42. Pietras EM, Lakshminarasimhan R, Techner JM, et al. Re-entry into quiescence protects hematopoietic stem cells from the killing effect of chronic exposure to type I interferons. J Exp Med 2014; 211 (2): 245–62.
43. Fermo E, Bianchi P, Barcellini W, et al. Immunoregulatory cytokine polymorphisms in Italian patients affected by paroxysmal nocturnal haemoglobinuria and aplastic anaemia. Eur J Immunogenet 2004; 31: 267–9.
44. Young NS, Scheinberg P, Calado RT. Aplastic anemia. Curr Opin Hematol 2008; 15: 162–8.
45. Kitagawa M, Saito I, Kuwata T, et al. Overexpression of tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma by bone marrow cells from patients with myelodysplastic syndromes. Leukemia 1997; 11: 2049–54.
46. Xu W, Xu L, Lu H, et al. The immunosuppressive effect of gossypol in mice is mediated by inhibition of lymphocyte proliferation and by induction of cell apoptosis. Acta Pharmacol Sin 2009; 30: 597–604.
47. Liu GZ. Clinical studies of gossypol as a male contraceptive. Reproduction 1987; 5: 189–92.
48. Weinbaurer GF, Rovan E, Frick J. Toxicity of gossypol at antifertility dosages in male rats. Statistical analyses of lethal rates and body weight responses. Andrologyia 1983; 15: 213–21.
49. Coutinho EM. Gossypol: a contraceptive for men. Contraception 2002; 65 (4): 259–63.
50. Васечкина Л.И., Азарова Е.К., Акинфиев А.В. Алгоритмы комплексной терапии часто болеющих детей. Лечащий врач. 2015 [Vasechkina LI, Azarova EK, Akinfiev AV. Algoritmy kompleksnoi terapii chasto boleiushchikh detei. Lechashchii vrach. 2015 (in Russian)].
51. Романцов М.Г., Ершов Ф.И. Часто болеющие дети: современная фармакотерапия. М.: ГЭОТАР-Медиа, 2006 [Romantsov MG, Ershov FI. Frequently ill children: modern pharmacotherapy. Moscow: GEOTAR-Media, 2006 (in Russian)].
52. Александрова В.А. Основы иммунной системы желудочно-кишечного тракта. Учебно-методическое пособие. СПб.: МАПО, 2006 [Alexandrova VA. Basics of the immune system of the gastrointestinal tract. Study guide. Saint Petersburg: MAPO, 2006 (in Russian)].
53. Шишкова В.Н. Возможности современных препаратов в профилактике и лечении ОРВИ и гриппа. РМЖ. 2016; 6: 395–400 [Shishkova VN. Vozmozhnosti sovremennykh preparatov v profilaktike i lechenii ORVI i grippa. RMZh. 2016; 6: 395–400 (in Russian)].
54. Ершов Ф.И., Наровлянский А.Н. Использование индукторов интерферона при вирусных инфекциях. Вопросы вирусологии. 2015; 60 (2): 5–10 [Ershov FI, Narovlianskii AN. Ispol'zovanie induktorov interferona pri virusnykh infektsiiakh. Voprosy virusologii. 2015; 60 (2): 5–10 (in Russian)].

________________________________________________

1. Acute respiratory tract infections in children. Diagnostics, treatment, prevention: clinical guidelines. NA Geppe (Ed.). Moscow: MedKom-Pro, 2018 (in Russian)
2. Vikulov GKh. Novye i vozvrashchaiushchiesia respiratornye virusnye infektsii: algoritmy diagnostiki i terapii. RMZh. Meditsinskoe obozrenie. 2018; 2 (8–1): 5–11 (in Russian)
3. Garashchenko TI, Garashchenko MV, Mezentseva MV. Kliniko-immunologicheskoye obosnovaniye gomeopaticheskikh preparatov v profilaktike i lechenii grippa i ORVI. Rus. med. zhurn. 2005; 13 (21): 1432–7 (in Russian)
4. Garashchenko MV, Il'yenko LI, Garashchenko TI, Mezentsenva MV. Kliniko-immunologicheskoye obosnovaniye primeneniya Aflubina v profilaktike i lechenii virusnykh zabolevaniy respiratornogo trakta u detey. Detskiye infektsii. 2005; 3: 49–3 (in Russian)
5. Ilyenko LI, Gureev AN, Gainova LV, Bogdanova SV. Evaluation of the clinical efficacy of complex homeopathic medicines from the standpoint of evidence-based medicine. In: Homeopathic Yearbook – 2019. Collection of materials of the XXIX Scientific and Practical Conference. 2019; p. 138–42 (in Russian)
6. PRIMA: Pediatric recommendations for immunomodulatory drugs in outpatient practice (consensus). 2nd ed., rev. and add. Moscow: RG-Press, 2017 (in Russian)
7. Ilienko LI, Garashchenko TI, Kholodova IN, et al. A frequently ill child. Clinical and experimental and economic substantiation of new technologies for preventive and restorative measures in outpatient settings. Moscow, 2008 (in Russian)
8. Ershov FI. Ratsional'naia farmakoterapiia grippa i ORVI. Farmatsevticheskii vestnik. 2003; 33: 39–43 (in Russian)
9. Eropkin MIu, Gudkova TM, Danilenko DM, et al. Pandemicheskii gripp 2009 g. v Rossii. RMZh. 2010; 18 (7): 410–5 (in Russian)
10. Sel'kova EP, Semenenko TA, Leneva IA, Burtseva MI. Gomeopaticheskii preparat Otsillokoktsinum v lechenii i profilaktike grippa i ORVI. Trudnyi patsient. 2006; 11 (in Russian)
11. Romantsov MG, Mel'nikova IIu, Smagina AN, et al. Effektivnost' tsikloferona i otsenka ego bezopasnosti pri respiratornykh virusnykh infektsiiakh u detei. Fundamental'nye issledovaniia. 2012; 2: 208–14 (in Russian)
12. Rational pharmacotherapy of frequently ill children. A guide for pediatricians, family doctors, medical students. MG Romantsov (Ed.). Saint Petersburg, 2006 (in Russian)
13. Farber IM, Geppe NA, Reikhart DV, et al. Terapiia grippa i prochikh ORVI u detei mladshego i srednego shkol'nogo vozrasta: vliianie preparata IngavirinR na intoksikatsionnyi, likhoradochnyi i kataral'nyi sindromy. Ros. vestn. perinatologii i pediatrii. 2016; 61 (2): 115–20 (in Russian)
14. Ershov FI. Antiviral drugs: a reference book. 2nd ed. Moscow: GEOTAR-Media, 2006 (in Russian)
15. Maksakova VL, Vasil'eva IA, Erofeeva MK. Primenenie preparata Kagotsel dlia lecheniia i profilaktiki grippa i drugikh ostrykh respiratornykh virusnykh infektsii. Medlain-ekspress. 2009; 1: 42–5 (in Russian)
16. Sologub TV, Shul'diakov AA, Romantsov MG, et al. Tsikloferon kak sredstvo lecheniia i ekstrennoi profilaktiki grippa i ORVI (mnogotsentrovoe randomizirovannoe kontrol'no-sravnitel'noe issledovanie). Antibiotiki i khimioterapiia. 2009; 7–8: 30–6 (in Russian)
17. Karetkina GN. Primenenie induktorov interferonov dlia lecheniia i profilaktiki grippa i drugikh ostrykh respiratornykh virusnykh infektsii. Lechashchii vrach. 2009; 10: 1–5 (in Russian)
18. Romantsov MG, Sel'kova EP, Garashchenko MV, et al. Povyshenie estestvennoi rezistentnosti detei s tsel'iu profilaktiki grippa i ORVI (rezul'taty mnogotsentrovykh randomizirovannykh issledovanii). Antibiotiki i khimioterapiia. 2009; 9–10: 37–41 (in Russian)
19. Novikova IA. Tselesoobraznost' primeneniia preparatov interferonov dlia profilaktiki i lecheniia ORVI. Meditsinskie novosti. 2017; 1: 27–30 (in Russian)
20. Ershov FI, Narovlianskii AN. Teoreticheskie i prikladnye aspekty sistemy interferonov: k 60-letiiu otkrytiia interferonov. Voprosy virusologii. 2018; 63 (1): 10–8 (in Russian)
21. Romantsov MG, Shul'diakov AA, Ershov FI, et al. Induktory endogennogo interferona v infektologii (Nauchnyi obzor). Profilakticheskaia meditsina. 2013; 1–2: 77–83 (in Russian)
22. Forsbach A, Muller Ch, Montino C, et al. Negative regulation of the type I interferon signaling pathway by synthetic Toll-like receptor 7 ligands. J Interferon Cytokine Res 2012; 6: 254–68.
23. Titov LP, Karpov IA. Protivovirusnyi immunitet: molekuliarno-kletochnye mekhanizmy, ­zakonomernosti razvitiia i immunopatologiia. Med. zhurn. 2007; 1: 4–14 (in Russian)
24. Booy S, Hofland L, van Eijck C. Potentials of interferon therapy in the treatment of pancreatic cancer. J Interferon Cytokine Res 2015; 35: 327–39.
25. Тarhini AA, Lee SJ, Li X, et al. E3611-A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-a2b in Advanced Melanoma. Clin Cancer Res 2019; 25 (2): 524–32.
26. Theocharis SE, Margeli AP, Tsokos MG. Alpha 2b-interferon inhibits rat liver regeneration after partial hepatectomy without affecting thymidine kinase activity. J Lab Clin Med 1995; 125 (5): 588–96.
27. Kaneko N, Kudo K, Mabuchi T, et al. Suppression of cell proliferation by interferon-alpha through interleukin-1 production in adult rat dentate gyrus. Neuropsychopharmacology 2006; 31 (12): 2619–26.
28. Yaar M, Karassik RL, Schnipper LE, et al. Effects of alpha and beta interferons on cultured human keratinocytes. J Invest Dermatol 1985; 85 (1): 70–4.
29. Elias JA, Jimenez SA, Freundlich B. Recombinant gamma, alpha, and beta interferon regulation of human lung fibroblast proliferation. Am Rev Respir Dis 1987; 135 (1): 62–5.
30. Vorotelyak EA, Alpeeva EV. Evaluation of the antiproliferative effect of interferon a2b and Oscillococcinum on various human and murine cells cultures. Epub ahead of print.
31. Rogovaia OS, Izmailova LSh, Serbina OO. K voprosu ob izuchenii patogeneza antiproliferativnogo deistviia protivovirusnykh preparatov. Infektsionnye bolezni. 2020; 18 (2): 48–56 (in Russian)
32. Khabriev RU. Guidelines for experimental (preclinical) study of new pharmacological substances. Moscow, 2005 (in Russian)
33. Valiev TT. Interferon clinical use: modern view on efficacy and safety. Literature review. ­Pediatrics. Consilium Medicum. 2020; 3 (in Russian) DOI: 10.26442/26586630.2020.3.200286
34. Verma A, Deb DK, Sassano A, et al. Activation of the p38 mitogen-activated protein kinase mediates the suppressive effects of type I interferons and transforming growth factor-b on normal hematopoiesis. J Biol Chem 2002; 277: 7726–35.
35. Orford KW, Scadden DT. Deconstructing stem cell self-renewal: genetic insights into cell-cycle regulation. Nat Rev Genet 2008; 9: 115–28.
36. Baldridge MT, King KY, Goodell MA. Inflammatory signals regulate hematopoietic stem cells. Trends Immunol 2011; 32: 57–65.
37. Selleri C, Sato T, Anderson S, et al. Interferon-gamma and tumor necrosis factoralpha suppress both early and late stages of hematopoiesis and induce programmed cell death. J Cell Physiol 1995; 165: 538–46.
38. Broxmeyer HE, Williams DE, Lu L, et al. The suppressive influences of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: synergism of tumor necrosis factor and interferon-gamma. J Immunol 1986; 136: 4487–95.
39. Hwang JH, Kim SW, Lee HJ, et al. Interferon gamma has dual potential in inhibiting or promoting survival and growth of hematopoietic progenitors: interactions with stromal cell-derived factor 1. Int J Hematol 2006; 84: 143–50.
40. Zeng W, Miyazato A, Chen G, et al. Interferon-gamma-induced gene expression in CD34 cells: identification of pathologic cytokine-specific signature profiles. Blood 2006; 107: 167–75.
41. Baldridge MT, King KY, Boles NC, et al. Quiescent haematopoietic stem cells are activated by IFN-g in response to chronic infection. Nature 2010; 465: 793–7.
42. Pietras EM, Lakshminarasimhan R, Techner JM, et al. Re-entry into quiescence protects hematopoietic stem cells from the killing effect of chronic exposure to type I interferons. J Exp Med 2014; 211 (2): 245–62.
43. Fermo E, Bianchi P, Barcellini W, et al. Immunoregulatory cytokine polymorphisms in Italian patients affected by paroxysmal nocturnal haemoglobinuria and aplastic anaemia. Eur J Immunogenet 2004; 31: 267–9.
44. Young NS, Scheinberg P, Calado RT. Aplastic anemia. Curr Opin Hematol 2008; 15: 162–8.
45. Kitagawa M, Saito I, Kuwata T, et al. Overexpression of tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma by bone marrow cells from patients with myelodysplastic syndromes. Leukemia 1997; 11: 2049–54.
46. Xu W, Xu L, Lu H, et al. The immunosuppressive effect of gossypol in mice is mediated by inhibition of lymphocyte proliferation and by induction of cell apoptosis. Acta Pharmacol Sin 2009; 30: 597–604.
47. Liu GZ. Clinical studies of gossypol as a male contraceptive. Reproduction 1987; 5: 189–92.
48. Weinbaurer GF, Rovan E, Frick J. Toxicity of gossypol at antifertility dosages in male rats. Statistical analyses of lethal rates and body weight responses. Andrologyia 1983; 15: 213–21.
49. Coutinho EM. Gossypol: a contraceptive for men. Contraception 2002; 65 (4): 259–63.
50. Vasechkina LI, Azarova EK, Akinfiev AV. Algoritmy kompleksnoi terapii chasto boleiushchikh detei. Lechashchii vrach. 2015 (in Russian)
51. Romantsov MG, Ershov FI. Frequently ill children: modern pharmacotherapy. Moscow: GEOTAR-Media, 2006 (in Russian)
52. Alexandrova VA. Basics of the immune system of the gastrointestinal tract. Study guide. Saint Petersburg: MAPO, 2006 (in Russian)
53. Shishkova VN. Vozmozhnosti sovremennykh preparatov v profilaktike i lechenii ORVI i grippa. RMZh. 2016; 6: 395–400 (in Russian)
54. Ershov FI, Narovlianskii AN. Ispol'zovanie induktorov interferona pri virusnykh infektsiiakh. Voprosy virusologii. 2015; 60 (2): 5–10 (in Russian)

С.В. Богданова*1, Т.И. Гаращенко1,2, Л.И. Ильенко1

1 ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России, Москва, Россия;
2 ФГБУ «Национальный медицинский исследовательский центр оториноларингологии» ФМБА России, Москва, Россия
*2891photina@mail.ru

________________________________________________

Svetlana V. Bogdanova*1, Tatiana I. Garashchenko1,2, Lidiia I. Il'enko1

1 Pirogov Russian National Research Medical University, Moscow, Russia;
2 National Medical Research Center of Otorhinolaryngology, Moscow, Russia
*2891photina@mail.ru